000267555 001__ 267555
000267555 005__ 20240229154921.0
000267555 0247_ $$2doi$$a10.3390/ijms24031943
000267555 0247_ $$2pmid$$apmid:36768267
000267555 0247_ $$2ISSN$$a1422-0067
000267555 0247_ $$2ISSN$$a1661-6596
000267555 037__ $$aDKFZ-2023-00333
000267555 041__ $$aEnglish
000267555 082__ $$a540
000267555 1001_ $$aLiu, Yibin$$b0
000267555 245__ $$aDefinition and Characterization of SOX11-Derived T Cell Epitopes towards Immunotherapy of Glioma.
000267555 260__ $$aBasel$$bMolecular Diversity Preservation International$$c2023
000267555 3367_ $$2DRIVER$$aarticle
000267555 3367_ $$2DataCite$$aOutput Types/Journal article
000267555 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1676300662_32050
000267555 3367_ $$2BibTeX$$aARTICLE
000267555 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000267555 3367_ $$00$$2EndNote$$aJournal Article
000267555 520__ $$aThe transcription factor SOX11 is a tumor-associated antigen with low expression in normal cells, but overexpression in glioblastoma (GBM). So far, conventional surgery, chemotherapy, and radiotherapy have not substantially improved the dismal prognosis of relapsed/refractory GBM patients. Immunotherapy is considered a promising strategy against GBM, but there is a fervent need for better immunotargets in GBM. To this end, we performed an in silico prediction study on SOX11, which primarily yielded ten promising HLA-A*0201-restricted peptides derived from SOX11. We defined a novel peptide FMACSPVAL, which had the highest score according to in silico prediction (6.02 nM by NetMHC-4.0) and showed an exquisite binding affinity to the HLA-A*0201 molecule in the peptide-binding assays. In the IFN-γ ELISPOT assays, FMACSPVAL demonstrated a high efficiency for generating SOX11-specific CD8+ T cells. Nine out of thirty-two healthy donors showed a positive response to SOX11, as assessed by the ELISPOT assays. Therefore, this novel antigen peptide epitope seems to be promising as a target for T cell-based immunotherapy in GBM. The adoptive transfer of in vitro elicited SOX11-specific CD8+ T cells constitutes a potential approach for the treatment of GBM patients.
000267555 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000267555 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000267555 650_7 $$2Other$$aHLA-A*0201
000267555 650_7 $$2Other$$aSOX11
000267555 650_7 $$2Other$$aglioma
000267555 650_7 $$2Other$$aimmunotherapy
000267555 650_7 $$2Other$$atumor-associated antigen
000267555 7001_ $$aKeib, Anna$$b1
000267555 7001_ $$aNeuber, Brigitte$$b2
000267555 7001_ $$aWang, Lei$$b3
000267555 7001_ $$0P:(DE-He78)3743a1b712edca2ffa829b7096d7037e$$aRiemer, Angelika$$b4$$udkfz
000267555 7001_ $$0P:(DE-He78)ec22a465429f245d6ef43a2329223262$$aBonsack, Maria$$b5$$udkfz
000267555 7001_ $$aHückelhoven-Krauss, Angela$$b6
000267555 7001_ $$aSchmitt, Anita$$b7
000267555 7001_ $$aMüller-Tidow, Carsten$$b8
000267555 7001_ $$aSchmitt, Michael$$b9
000267555 773__ $$0PERI:(DE-600)2019364-6$$a10.3390/ijms24031943$$gVol. 24, no. 3, p. 1943 -$$n3$$p1943$$tInternational journal of molecular sciences$$v24$$x1422-0067$$y2023
000267555 909CO $$ooai:inrepo02.dkfz.de:267555$$pVDB
000267555 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3743a1b712edca2ffa829b7096d7037e$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000267555 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ec22a465429f245d6ef43a2329223262$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000267555 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000267555 9141_ $$y2023
000267555 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-09-04T08:27:04Z
000267555 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-25
000267555 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-25
000267555 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-25
000267555 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-25
000267555 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J MOL SCI : 2022$$d2023-08-25
000267555 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000267555 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000267555 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
000267555 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-07T16:31:47Z
000267555 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-07T16:31:47Z
000267555 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-07T16:31:47Z
000267555 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000267555 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000267555 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-08-25
000267555 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
000267555 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
000267555 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J MOL SCI : 2022$$d2023-08-25
000267555 9201_ $$0I:(DE-He78)F130-20160331$$kF130$$lF130 Immuntherapie und -prävention$$x0
000267555 980__ $$ajournal
000267555 980__ $$aVDB
000267555 980__ $$aI:(DE-He78)F130-20160331
000267555 980__ $$aUNRESTRICTED